Bioprocess Engineering of Mammalian Cell Culture

哺乳动物细胞培养的生物过程工程

• 批准号: RGPIN-2015-03736
• 负责人: Piret, James
• 金额: $ 2.91万
• 依托单位: University of British Columbia
• 依托单位国家: 加拿大
• 项目类别: Discovery Grants Program - Individual
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=708327
• 关键词: Bioprocess; Engineering; Mammalian; Cell; Culture

Mammalian cell cultures have become the dominant technology for the production of biological therapeutics. These cultures are also increasingly used for the research and development of novel immunotherapies and stem cell therapies, used to treat injuries and chronic diseases. The great promise of these emerging treatments comes with great challenges, many of those in the field of cell culture process engineering. The long-term goal of this program is to enable safer and more economical manufacture of mammalian cell products. This will be achieved by recently developed technologies to perform novel research that will increase the understanding of cell culture processes. We should thereby contribute both to accelerated process development as well more effectively optimized bioprocesses. This will include work in the relatively simple context of mammalian cell protein manufacturing, as well as the more complex analysis of therapeutic cell cultures. In particular, improved process analytical technologies will be developed to greatly increase the high-throughput analysis of mammalian cell culture populations and accelerate the selection of specific cells that are most suitable for manufacturing. The development of reliable and economical means of mammalian cell manufacturing is essential to ensure that many promising emerging health care technologies actually become widely available to the patients who need them. Ultimately, increased access to safe and affordable cell culture products will improve the quality of many thousands of Canadian lives. UBC and Canadian multidisciplinary groups are among the leaders in this area of research. Exporting these technologies and knowledge should benefit populations around the world as well as translate into substantial commercial benefits for Canadians.

哺乳动物细胞培养已成为生产生物治疗剂的主导技术。这些培养物也越来越多地用于新型免疫疗法和干细胞疗法的研究和开发，用于治疗损伤和慢性疾病。 这些新兴治疗方法的巨大前景伴随着巨大的挑战，其中许多是在细胞培养工艺工程领域。 该计划的长期目标是使哺乳动物细胞产品的生产更安全，更经济。 这将通过最近开发的技术来实现，以进行新的研究，从而增加对细胞培养过程的理解。 因此，我们应该为加速工艺开发以及更有效地优化生物工艺做出贡献。 这将包括在哺乳动物细胞蛋白质制造的相对简单的背景下的工作，以及治疗性细胞培养物的更复杂的分析。 特别是，将开发改进的过程分析技术，以大大增加哺乳动物细胞培养群体的高通量分析，并加速选择最适合生产的特定细胞。 开发可靠和经济的哺乳动物细胞制造方法对于确保许多有前途的新兴医疗保健技术实际上广泛提供给需要它们的患者至关重要。最终，增加获得安全和负担得起的细胞培养产品的机会将改善成千上万加拿大人的生活质量。 UBC和加拿大多学科小组是这一研究领域的领导者。出口这些技术和知识将使世界各地的人民受益，并为加拿大人带来巨大的商业利益。